Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces will be presenting at the ShareSoc Growth Company Seminar in London on Wednesday, 11 September 2019.
Jamal Rushdy, CEO, will provide an update regarding progress highlighted during the recent Annual General Meeting, and the Company's prospects for growth.
The event will take place at the Offices of Link Asset Services, 65 Gresham Street, London EC2V 7NQ. Presentations will start at 5.30pm.
Further details of the event, along with a registration form, are available at:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence update Proactive London's Andrew Scott on first half performance - their third consecutive six-month period of double-digit sales growth.
Revenues increased by 14% to £2.23mln in the period ended September 30. Tissue sales more...